亚太药业：预计2025年净利同比增长192.06%-250.47%

Core Viewpoint - Asia-Pacific Pharmaceutical (002370) expects to achieve operating revenue of 350 million to 370 million yuan and a net profit attributable to shareholders of 100 million to 120 million yuan for the year 2025, representing a year-on-year growth of 192.06% to 250.47% [4] Financial Performance - The company anticipates a non-recurring net profit loss of 42 million to 60 million yuan, compared to a loss of 28.13 million yuan in the same period last year [4] - Basic earnings per share are projected to be between 0.13 yuan and 0.16 yuan [4] Valuation Metrics - As of January 30, the company's price-to-earnings (P/E) ratio (TTM) is approximately 44.18 to 53.02 times, the price-to-book (P/B) ratio (LF) is about 4.73 times, and the price-to-sales (P/S) ratio (TTM) is around 14.73 times [4] Business Operations - The main business of the company involves pharmaceutical manufacturing, including the research, production, and sales of chemical preparations [11] - The increase in profit for 2025 is attributed to the sale of the wholly-owned subsidiary Shaoxing Xingya Pharmaceutical Co., Ltd., which is expected to add approximately 149 million yuan to the company's total profit for the year (non-recurring gains) [11]